Lupus Nephritis Therapeutics Pipeline 2018, Clinical Trials, Collaboration and Developments

Lupus Nephritis TherapeuticsLupus nephritis is a type of inflammation which is caused by an autoimmune disease, systemic lupus erythematosus. The body’s own cells are attacked by body’s immune system due to the formation of autoantibodies, in the case of systemic lupus erythematosus. The signs and symptoms of lupus nephritis include foamy urine, high blood pressure, and edema in legs, face, feet, and ankles. Kidney problems also occur in patients with lupus nephritis that can cause fever, muscle pain, red rashes, and joint pain. Systemic lupus erythematosus can affect skin, kidney, pericardium, nervous system and lungs. It has been observed that women are much susceptible to systemic lupus erythematosus than men. Astellas Pharma, Inc. is in the process of developing tacrolimus as an immunosuppressive drug for the treatment of lupus nephritis. Human Genome Sciences, Inc. is in the process of developing belimumab as a B-lymphocyte stimulator for the treatment of lupus nephritis. Some of the companies having the pipeline of lupus nephritis include Human Genome Sciences, Inc., AstraZeneca plc, Asahi Kasei Pharma Corporation, and others.

Explore Report Sample at@ https://www.psmarketresearch.com/market-analysis/lupus-nephritis-therapeutics-pipeline-analysis/report-sample

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Advertisements

Macular Edema Therapeutics Pipeline 2018 – Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy & Regulatory Landscape

Macular Edema Therapeutics Pipeline

Macular edema causes the building-up of fluid in macula region of the eye. The macula is a light sensitive tissue, present at the center of the retina and is responsible for the sharp, straight headed vision. Building-up of fluid in macula region leads the vision to distort. Diabetic retinopathy (which is most common in diabetic patients) is observed as the common cause of macular edema. However, macular edema can also occur after surgery associated with age related macular degeneration or inflammatory disease of the eye. Blurred vision and vision loss are observed in most of the patients with macular edema. The Shahid Beheshti University of Medical Sciences is in the process of developing bevacizumab as an angiogenesis inhibitor for the treatment of macular edema. Bayer AG is in the process of developing aflibercept as a vascular endothelial growth factor-A inhibitor for the treatment of macular edema. Some companies having the pipeline of macular edema include Clearside Biomedical, Inc., Chengdu Kanghong Biotech Co., Ltd., Novartis AG, and others.

Browse Report Sample at@ https://www.psmarketresearch.com/market-analysis/macular-edema-therapeutics-pipeline-analysis/report-sample

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Postherpetic Neuralgia Therapeutics Pipeline – Recent Study Including Growth Factors, Analysis and Key Players

Postherpetic neuralgia is a type of pain that occur due to nerve damage. The disease is one of the complications of shingles rash. Postherpetic neuralgia can be symptomatized by pain in the nerves, sensitive and itchy skin, muscle weakness, tremor, and paralysis. Aging, acute pain and severe rash during shingles, and lower immunity are the risk factors for developing poatherpetic neuralgia. The diagnosis of postherpetic neuralgia involves practical and accessible questionnaires. Novartis AG is in the process of developing EMA401 as an angiotensin type II receptor antagonist for the treatment of postherpetic neuralgia. ContraVir Pharmaceuticals, Inc. is in the process of developing FV-100 as a virus replication inhibitor for the treatment of postherpetic neuralgia. Some of the companies and universities having the pipeline of postherpetic neuralgia include ContraVir Pharmaceuticals, Inc., University of British Columbia, Jiangsu HengRui Medicine Co., Ltd., and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/postherpetic-neuralgia-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/postherpetic-neuralgia-therapeutics-pipeline-analysis

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

 

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Prader-Willi Syndrome Therapeutics – Pipeline Review 2018

Prader-willi syndrome (PWS) is a genetic disorder that causes alteration in eating, behaviour and mood, intellectual development, and physical growth. The disease occurs due to mutation in chromosome 15, which regulate the gene expression. The inability to control eating is one of the main symptoms of PWS. The physical symptoms of PWS generally prompts the occurrence of the disease in the new-born. There are few criteria that defines PWS, including extremely weak muscles, feeding difficulties, uncontrollable overeating, rapid weight gain, and reduced development of genital organs. The University of Florida is in the process of developing oxytocin as an oxytocin receptor agonist for the treatment of PWS. LG Life Sciences Ltd. is in the process of developing eutropin as a somatotropin receptor agonist for the treatment of PWS. Some of the companies and universities having the pipeline of PWS include LG Life Sciences Ltd., University of Florida, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/prader-willi-syndrome-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/prader-willi-syndrome-therapeutics-pipeline-analysis

 

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:

P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Microscopic Polyangiitis Therapeutics Pipeline 2018 – Patent, Designation and Collaboration

Microscopic Polyangiitis TherapeuticsMicroscopic polyangiitis is an inflammatory disorder that leads to the damage of organs such as kidneys, lungs, skin, joints, and nerves. The disease can be symptomatized by weight loss, inflammation of the kidneys, skin lesions, fever, nerve damage, skin rash, muscle and joint pain, loss of sensation, seizures, abdominal pain, and cough. However, the cause of microscopic polyangiitis is unknown, but it is thought that the overactive immune system causes the inflammation in the tissues and blood vessels. The Chiba University is in the process of developing glucocorticoids for the treatment of microscopic polyangiitis. ChemoCentryx, Inc. is also in the process of developing avacopan (CCX168) as a C5a receptor antagonist for the treatment of microscopic polyangiitis. Some of the companies having the pipeline of microscopic polyangiitis include Amgen plc, ChemoCentryx, Inc., and others.

Explore Report at: https://www.psmarketresearch.com/market-analysis/microscopic-polyangiitis-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/microscopic-polyangiitis-therapeutics-pipeline-analysis/report-sample

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Multiple System Atrophy Therapeutics – Pipeline Analysis, Clinical Trials, Designation and Collaboration

Multiple System Atrophy Therapeutics Pipeline Analysis 2018

Multiple System Atrophy TherapeuticsMultiple system atrophy is a type of neurodegenerative disorder that affects movement of the body and the autonomic nervous system which leads to loss of function and death of the nerve cells in spinal cord and brain. Multiple system atrophy can be symptomatized by erectile dysfunction, bladder control and fainting spells. Due to motor nervous system impairment, difficulties with speech and gait, along with tremor and rigidity occurs. However, the cause of the disease is still unknown, but it has been observed that the accumulation of alpha synuclein causes the degradation of nerve cells in the brain and spinal cord. The University Hospital, Toulouse is in the process of developing L-Threo DOPS as a synthetic precursor of norepinephrine, for the treatment of multiple system atrophy. The Vanderbilt University is in the process of developing BQ-123 as an endothelin receptor (ETA) antagonist for the treatment of multiple system atrophy. Some of the universities and companies having the pipeline of multiple system atrophy include Vanderbilt University, New York University School of Medicine, CORESTEM, Inc. and others.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/multiple-system-atrophy-therapeutics-pipeline-analysis/report-sample

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=multiple-system-atrophy-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

 

Immune Checkpoint Inhibitors Market – Pipeline Analysis, Size, Share and Demand, 2023

Immune Checkpoint Inhibitors MarketThe global immune checkpoint inhibitors market is expected to witness significant growth as these are proven to be more effective therapy in shrinking tumor in higher proportion of patients, as compared to other immunotherapies. Immune checkpoint inhibitors are applicable to a wider range of tumor types such as advanced or metastatic non-small cell lung cancer, renal cancer and melanoma. These inhibitors lower the rate of severe toxicities and immune-mediated side-effects. These are also convenient to administer and yield a good response rate of any single-agent immunotherapy.

Get Report Sample at: https://www.psmarketresearch.com/market-analysis/immune-checkpoint-inhibitors-market/report-sample

The pharmaceutical companies are actively involved in the research and development of drug for immune checkpoint inhibitors. The pipeline of immune checkpoint inhibitors is rich with more than 50 drugs. In November 2016, Bristol-Myers Squibb Company and Infinity Pharmaceuticals collaborated to check the efficacy of combination of Opdivo (a PD-1 inhibitor monoclonal antibody) and IPI-549 (a phosphoinositide-3-kinase gamma inhibitor) in patients with advanced solid tumors.

Immune checkpoints comprised of cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitors and PD-1 and PD-L1 inhibitors. CTLA-4 drug are molecules used to regulate, stimulate or inactivate the immune cells. PD-1 is found on the surface of cancer cells and it is used by tumors to evade the immune system; therefore, PD-1 inhibitor blocks PD-1 action and enables the body to attack and kill cancer cells. PD-L1 is a transmembrane protein of 40kDa that helps in suppressing the immune system during tissue allograft, pregnancy, autoimmune disease, hepatitis and other diseases.

Immune checkpoint inhibitors are showing good efficacy with PD-1 and PD-L1 inhibitors and CTLA-4 inhibitors. Yervoy, an anti-CTLA-4 product of Bristol-Myers Squibb Company got approved in the year 2011. The increased use of combination therapy of PD-1 and PD-L1 inhibitors represent a new signal of immunotherapeutics, which is expected to alter the standard of care for cancer across the globe. However, the development of effective immunotherapy presents some challenges due to complex pathophysiology of cancer and difficulty in managing treatment related toxic effects, which is expected to hamper the growth of the global market to some extent.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=immune-checkpoint-inhibitors-market

Some of the key players operating in the global market are Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Regeneron Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd., and TG Therapeutics, Inc.

Chronic Pain Treatment Market – Pipeline Analysis, Size and Growth, 2023

Chronic Pain TreatmentThe global chronic pain treatment market is expected to witness considerable growth due to current unmet medical need of chronic pain, technological advancement in pain therapeutic and diagnostic test, and increasing number of chronic diseases such as cancer, arthritis, and diabetes mellitus. In addition, increasing geriatric population and increasing disposable income are supporting the growth of the global chronic pain market. The pharmaceutical companies are actively involved in the research and development of drugs for chronic pain. Camurus is developing CAM2038, long-acting subcutaneous buprenorphine injections for the treatment of opioid dependence and pain.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/chronic-pain-treatment-market/report-sample

Chronic pain is defined as the pain that persists for more than 3 months or longer. It adversely affects patient’s quality of life that may limit a person’s movements, which can interfere with daily activities. This difficulty in carrying out work related or other activities can lead to disability and despair. Chronic pain persists and sends pain signals to the nervous system for weeks, months or even years. It also affects the peripheral and central nervous system called neuropathy that result from damage to or pathological changes of the peripheral or central nervous system. The actual cause of chronic pain is unknown. Some people feel chronic pain without having any past injury or evidence of body damage.

A large number of pharmaceutical companies are working for the research and development of drugs for chronic pain treatment. The pipeline of the chronic pain treatment drug candidate is rich. However, certain factors such as high treatment cost through branded drugs and decreased patient compliance are the key factors for impeding the growth of the global market during the forecast period.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=chronic-pain-treatment-market

Some of the key players operating in the global chronic pain market are Pfizer, Inc., Cara Therapeutics, Inc., Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc., Allergan plc, Purdue Pharma L.P., Mallinckrodt plc, AstraZencea plc, Jazz Pharmaceuticals plc, and Nektar Therapeutics.

Personalized Medicine Market – Global Industry Analysis, Size and Growth, 2023

Personalized Medicine MarketThe global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/report-sample

The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.

National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=personalized-medicine-market

Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Natural Killer Cell Therapeutics Market – Pipeline Analysis, Share and Growth, 2023

Natural Killer Cell TherapeuticsThe global natural killer cell therapeutics market is expected to witness considerable growth due to increasing awareness regarding immunotherapy, advancement in technologies, high demand for safe and effective medication, reduction of side effects, high prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing incidences of infectious diseases. The regulatory bodies are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Some drug candidates, such as Mogamulizumab, Lorvotuzumab Mertansine, AFM 13, FPA144, and NKTT-120, got orphan drug designation and fast track designation for NK cell therapeutics.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/nk-cell-therapeutics-market/report-sample

The pipeline of NK cell therapeutics market is rich with more than 30 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NK cells. Kyowa Hakko Kirin Co., Ltd. has Mogamulizumab drug in its Phase III clinical trial for NK cells therapeutics. Increasing use of combination therapy of NK cells is also a potential growth driver for the growth of the global market. Use of NK cells with Chimeric Antigen Receptor (CAR) T-Cell therapy helps to enhance the efficacy of the medication.

NK cells are granular lymphocytes that provide innate immunity and first line of defense against viral infections and cancer. Natural killer cells are made up of 5–15% circulating lymphocytes. It is found in peripheral tissues including liver, peritoneal cavity, and placenta. NK cell are activated by interleukins that is capable of extravasations and infiltration into tissues.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nk-cell-therapeutics-market

Some of the key players operating in the global NK cells market are Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc.